The results of a recent study that was published in the journal of Circulation, suggest that low-density lipoprotein ...

Elevated Remnant Cholesterol tied to increased ASCVD events in Individuals With Diabetes suggests a study published in the ...

Silence Therapeutics stock falls despite lowering lipoprotein levels in a phase II study of zerlasiran likely due to concerns ...

Altered sphingolipid biosynthetic flux and lipoprotein trafficking contribute to trans fat-induced atherosclerosis - (https:/ ...

A study was conducted to determine the association between housing unaffordability and health outcomes and medication ...

Salk scientists have tracked the flow of trans fats using mouse models to describe the molecular mechanisms that cause trans fats to promote atherosclerotic cardiovascular disease (ASCVD), explaining ...

On Monday, Silence Therapeutics plc (NASDAQ:SLN) presented end-of-treatment data from its Phase 2 ALPACAR-360 study of ...

The recently launched National Action Plan on Obesity, Diabetes, and Modifiable Risk Factors for Atherosclerotic ...

Among participants in the landmark ORAL Surveillance study assigned to the JAK inhibitor tofacitinib (Xeljanz) and also using ...

New research describes how sphingolipids can also contribute to arterial plaques and atherosclerosis, revealing a new side to ...

Dutch clinical-stage biotech NewAmsterdam Pharma, which is focused on non-statin medicines for patients at risk of ...

NewAmsterdam Pharma (NAMS) stock falls as Wall Street reacts to Phase 3 data for its oral anti-cholesterol therapy. Read more ...